Home / Brands / PACIRA PHARMACEUTICALS
PACIRA PHARMACEUTICALS Recalls
4 recalls on record · March 6, 2013 to July 3, 2024 · Drugs
Recalls by year
13
19
24
Count of recall notices naming this brand, by the year the recall was announced. A quiet year is not proof of a safe year.
July 3, 2024DrugsFDA
PACIRA PHARMACEUTICALS INC recalls Zilretta (triamcinolone acetonide extended-release injectable suspension), 32 mg per vial, Rx only, Manufactured for: Pa
Hazard: Failed Dissolution Specifications - did not meet the acceptance criteria for IVR Level 3 testing at 9 months 2-8¿C followed by 6 weeks at 25¿C
June 19, 2024DrugsFDA
PACIRA PHARMACEUTICALS INC recalls Drug Vial Label: Zilretta¿ (triamcinolone acetonide extended-release injectable suspension), 32 mg per vial, Rx only, Ma
Hazard: Failed Stability Specifications - at 12 months 2-8 degrees C followed by 6 weeks at 25 degrees C.
December 11, 2019DrugsFDA
Pacira Pharmaceuticals, Inc. recalls EXPAREL, Bupivicaine Liposome Injectable Suspension, 1.3%, 266 mg/20 mL (13 mg/mL), Sterile, 20 mL vial, Rx only, Manufa
Hazard: Sub Potent Drug: Out of Specification (OOS)
March 6, 2013DrugsFDA
Pacira Pharmaceuticals, Inc. recalls EXPAREL (bupivacaine liposome injectable suspension), 1.3%, 266 mg/20 mL (13.3 mg/mL) single use vials, INVESTIGATIONAL
Hazard: Subpotent; bupivacaine